Omnicell
OMCL
374 hedge funds and large institutions have $4.04B invested in Omnicell in 2022 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 145 increasing their positions, 122 reducing their positions, and 58 closing their positions.
648% more call options, than puts
Call options by funds: $13.3M | Put options by funds: $1.78M
19% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 122
3% less funds holding
Funds holding: 385 → 374 (-11)
3.01% less ownership
Funds ownership: 107.79% → 104.78% (-3%)
12% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 58
25% less capital invested
Capital invested by funds: $5.42B → $4.04B (-$1.38B)
67% less funds holding in top 10
Funds holding in top 10: 9 → 3 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.4M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$32.2M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$24.1M |
| 4 |
Lazard Asset Management
New York
|
+$22.4M |
| 5 |
Goldman Sachs
New York
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$229M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$54.1M |
| 3 |
Neuberger Berman Group
New York
|
-$53.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$27.1M |
| 5 |
Morgan Stanley
New York
|
-$18.3M |
OMCL Hedge Fund Activity: Q3 2022 in Review
374 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Omnicell (OMCL) for Q3 2022, worth a combined $4.04B — down 25% from $5.42B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of OMCL and 51 opened new positions — a net loss of 7 holders — while 122 trimmed existing stakes and 145 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $36.4M. The largest seller was BlackRock, cutting an estimated $229M.
- 374 institutional investors held Omnicell (OMCL) as of Q3 2022, down from 385 in Q2 2022.
- Funds reported $4.04B of Omnicell stock for Q3 2022, down 25% quarter-over-quarter.
- 51 funds opened new Omnicell positions in Q3 2022 and 58 closed out, a net change of -7 holders.
- The largest Omnicell buyer in Q3 2022 was Citadel Advisors, an estimated $36.4M added.
- The largest Omnicell seller in Q3 2022 was BlackRock, an estimated $229M sold.
Based on aggregated 13F filings for Q3 2022.